ZY ZYMERGEN INC

Zymergen to Report Preliminary Fourth Quarter and Full Year 2021 Financial Results on March 22nd, 2022

Zymergen to Report Preliminary Fourth Quarter and Full Year 2021 Financial Results on March 22nd, 2022

EMERYVILLE, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”) today announced it will report preliminary financial results for the fourth quarter and full year 2021 after market close on Tuesday, March 22nd, 2022. The company’s management will host a conference call beginning at 1:30 PM Pacific Time / 4:30 PM Eastern Time to discuss its results, business developments and outlook.

A webcast of the conference call can be accessed at .

About Zymergen

Zymergen is a biotech company that designs and produces molecules, microbes and materials for diverse end markets. We partner with nature to make better products, a better way, for a better world.

Investor Contact

Carrie Mendivil



Media Contact

Mike Dulin



EN
16/03/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZYMERGEN INC

 PRESS RELEASE

Zymergen Expands Agreement with Octant to Scale Next-Generation Drug D...

Zymergen Expands Agreement with Octant to Scale Next-Generation Drug Discovery Platform Octant doubles its initial investment in Zymergen’s Automation Technology to significantly increase the scale and throughput of its drug discovery platform EMERYVILLE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”) today announced it has expanded its agreement with Octant to further scale their next-generation platform to develop breakthrough medicines. In May, five Reconfigurable Automation Carts, or RACs, to improve the throughput, efficiency, and reliability...

 PRESS RELEASE

Zymergen Announces R&D Supply Agreement with 3D4Makers to Provide New ...

Zymergen Announces R&D Supply Agreement with 3D4Makers to Provide New Polyimide for Use in High-Performance 3D Printing Applications EMERYVILLE, Calif., June 28, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”) today announced an R&D supply agreement to provide Zymergen Z2TM polyimide powder to 3D4Makers for use in high performance 3D printing applications. 3D4Makers will convert the powder to filament, offering its first-ever polyimide filament to customers for use across a wide range of applications including aerospace, automotive, and transportation. Polyimide is...

 PRESS RELEASE

Zymergen Sells Modular Automation System to Octant to Scale Next-Gener...

Zymergen Sells Modular Automation System to Octant to Scale Next-Generation Drug Discovery Platform EMERYVILLE, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”), today announced it has entered into an agreement with Octant for the sale of a modular automation system to scale Octant’s next-generation platform to develop breakthrough medicines. Zymergen’s complete automation solution includes modular hardware, modern web-based software, custom and turnkey workflows, and active monitoring and support. This technology will be incorporated into Octant’s ex...

 PRESS RELEASE

Zymergen Reports Preliminary First Quarter 2022 Financial Results

Zymergen Reports Preliminary First Quarter 2022 Financial Results EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen Inc. (“Zymergen” or the “Company”), today reported preliminary financial results for the first quarter ended March 31, 2022. “Our mission at Zymergen is to partner with nature to make better products, a better way, for a better world. One of the key transformations we have made is to create a nimble, disciplined product development process,” said Zymergen’s interim CEO, Jay Flatley. “We now have the infrastructure to support great execution...

 PRESS RELEASE

Zymergen to Participate in the BofA Securities 2022 Healthcare Confere...

Zymergen to Participate in the BofA Securities 2022 Healthcare Conference EMERYVILLE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”), today announced the company will be participating in the upcoming BofA Securities 2022 Healthcare Conference held in Las Vegas, NV. Zymergen’s management is scheduled to present on Tuesday, May 10th at 10:55 a.m. Pacific Time / 1:55 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: . About ZymergenZymergen is a bio...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch